['small cell lung cancer']
['rovalpituzumab tesirine', 'topotecan', 'dexamethasone']

        Inclusion Criteria:

          -  Participant must have histologically or cytologically confirmed advanced or metastatic
             Small Cell Lung Cancer (SCLC) with documented first disease progression during or
             following front-line platinum-based systemic regimen

          -  Tumor must have high Delta-like protein 3 (DLL3) expression defined as having ≥ 75%
             tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.

          -  Participant must have measurable disease, as defined per Response Evaluation Criteria
             in Solid Tumors (RECIST) version 1.1.

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1.

          -  Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity
             (excluding alopecia) prior to initiation of study drug administration.

        Exclusion Criteria:

          -  Participant has a documented history of a cerebral vascular event (stroke or transient
             ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms
             consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior
             to their first dose of study drug.

          -  Participant has known leptomeningeal metastases.

          -  Participant has received more than one prior systemic therapy regimen for SCLC.

          -  Participant had a serious infection within 2 weeks prior to randomization, including
             any Grade 3 or higher viral, bacterial, or fungal infection.

          -  Participant has a history of active malignancies other than SCLC within the past 2
             years prior to study entry, with the exception of in situ cancer which was curatively
             treated.

          -  Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I
             inhibitors.
      